Bone resorption is unchanged by liraglutide in type 2 diabetes patients: A randomised controlled trial

Keyphrases

• Randomized Controlled Trial 100%
• Type 2 Diabetic Patients 100%
• Liraglutide 100%
• Bone Resorption 100%
• Placebo 36%
• Bone Mineral Density 18%
• Hip Bone 18%
• Bone Turnover 18%
• Procollagen Type 1 N-terminal Propeptide (P1NP) 18%
• A1 Receptor 9%
• Beneficial Effects 9%
• Receptor Agonist 9%
• Between-group 9%
• Weight Loss 9%
• Glucagon-like 9%
• Glucose Metabolism 9%
• Antiresorptive 9%
• Collagen I 9%
• Double-blind Clinical Trial 9%
• Cross-linked 9%
• C-terminal Telopeptide 9%

Immunology and Microbiology

• Osteolysis 100%
• Bone Turnover 66%
• Hip 66%
• Amino Terminal Sequence 66%
• Bone Density 66%
• Animal Experiment 33%
• Agonist 33%
• Carboxy Terminal Sequence 33%
• Glucose Metabolism 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Randomized Controlled Trial 100%
• Non Insulin Dependent Diabetes Mellitus 100%
• Liraglutide 100%
• Placebo 36%
• Procollagen 18%
• Clinical Trial 9%
• Glucagon Like Peptide 1 Receptor Agonist 9%
• Telopeptide 9%